In Clinical Pharmacology & Therapeutics Floor Lubberman and colleagues showed that the intake of 600mg pazopanib with food resulted in a bioequivalent exposure and was preferred over a standard pazopanib dose without food. No differences were seen in GI-toxicities under both intake regimens. Patients seem to be more positive about their feelings about side effects and satisfaction with their therapy when pazopanib was taken with food. 41(68%) of the patients preferred the intake with continental breakfast.Pazopanib is taken fasted in a fixed oral daily dose of 800mg. We hypothesized that ingesting pazopanib with food may improve patients' comfort and reduce gastro-intestinal adverse events. Therefore we investigated the bio-equivalent dose of pazopanib when taken with food compared to 800mg pazopanib taken fasted. In addition we investigated the differences in GI-toxicity, patient satisfaction and patient's preference for either intake. The intake of 600mg pazopanib with food resulted in a bioequivalent exposure and was preferred over a standard pazopanib dose without food. No differences were seen in GI-toxicities under both intake regimens. Patients seem to be more positive about their feelings about side effects and satisfaction with their therapy when pazopanib was taken with food. 41(68%) of the patients preferred the intake with continental breakfast.
The effect of using pazopanib with food vs fasted on pharmacokinetics, patient safety and preference (DIET study).
Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP.
Floor Lubberman is member of theme Urological cancers.
Related news items
Social media posts on medication use during pregnancy often incorrect23 August 2019
Dutch social media regularly post about the safety of medicines for pregnant women. Many pregnant women use these posts as a source of information. A new analysis shows, however, that information found on social media about the risk of medication use often does not correspond with guidelines.read more
Hans van Bokhoven newly elected in Academia Europaea22 August 2019
The Academia Europaea is a functioning European Academy of Humanities, Letters and Sciences, composed of individual members.read more
Drug-induced interstitial lung disease in advanced breast cancer patients receiving everolimus22 August 2019
In Targeted Oncology, Annelieke Willemsen, Carla van Herpen and colleagues, showed that pulmonary function test with diffusion capacity of the lungs for carbon monoxide and serum biomarkers can be of aid to differentiate everolimus-related interstitial lung disease from other respiratory problems.read more
Publication in PNAS on dissecting EEC syndrome using single-cell RNA-seq22 August 2019
PhD candidates Eduardo Soares and Quan Xu in Jo Huiqing Zhou’s group in Molecular Developmental Biology, theme Reconstruction and regenerative medicine, have published a paper in PNAS on the disease mechanism of EEC syndrome using single-cell RNA-seq technology and patient-derived iPSCs.read more
Patient trust and participation in cell biological research21 August 2019
Alessandra Cambi and Gert Olthuis, discuss key ethical issues inherent in the development and the value of building trust and trustworthiness.read more
NWO grant for a tissue-generating patch to close diaphragmatic defects21 August 2019
Willeke Daamen and Toin van Kuppevelt, theme Reconstructive and regenerative medicine, were recently awarded a 690 k€ grant by NWO, domain Applied & Engineering Sciences, for the development of advanced patches for closure of diaphragmatic defects in children with congenital diaphragmatic hernia.read more